 Mark Clements
Concepts (498)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 99 | 2024 | 115 | 28.730 |
Why?
| | Blood Glucose | 48 | 2024 | 61 | 7.950 |
Why?
| | Blood Glucose Self-Monitoring | 35 | 2024 | 37 | 6.270 |
Why?
| | Hypoglycemia | 26 | 2024 | 31 | 6.140 |
Why?
| | Hypoglycemic Agents | 33 | 2024 | 36 | 5.870 |
Why?
| | Insulin | 35 | 2024 | 50 | 5.550 |
Why?
| | Humans | 145 | 2024 | 6896 | 4.680 |
Why?
| | Male | 97 | 2024 | 3337 | 4.060 |
Why?
| | Prostatic Neoplasms | 10 | 2024 | 34 | 3.700 |
Why?
| | Adolescent | 69 | 2024 | 2197 | 3.410 |
Why?
| | Diabetes Mellitus | 6 | 2024 | 20 | 3.380 |
Why?
| | Child | 72 | 2024 | 3364 | 3.340 |
Why?
| | Female | 83 | 2024 | 3525 | 3.330 |
Why?
| | Insulin Infusion Systems | 16 | 2024 | 17 | 3.270 |
Why?
| | Parents | 22 | 2023 | 157 | 3.180 |
Why?
| | Diabetes Mellitus, Type 2 | 12 | 2023 | 39 | 3.110 |
Why?
| | Hyperglycemia | 11 | 2024 | 13 | 2.880 |
Why?
| | Adult | 44 | 2024 | 1181 | 2.530 |
Why?
| | Child, Preschool | 35 | 2024 | 1569 | 2.340 |
Why?
| | Depression | 10 | 2023 | 69 | 2.330 |
Why?
| | Diabetic Ketoacidosis | 5 | 2024 | 6 | 2.060 |
Why?
| | Middle Aged | 31 | 2024 | 608 | 1.930 |
Why?
| | Mass Screening | 6 | 2024 | 35 | 1.800 |
Why?
| | Registries | 14 | 2024 | 92 | 1.750 |
Why?
| | Self Care | 5 | 2018 | 22 | 1.410 |
Why?
| | Early Detection of Cancer | 3 | 2024 | 10 | 1.390 |
Why?
| | Caregivers | 5 | 2022 | 40 | 1.390 |
Why?
| | Aged | 19 | 2024 | 378 | 1.350 |
Why?
| | Prostate-Specific Antigen | 5 | 2024 | 9 | 1.320 |
Why?
| | Telemedicine | 4 | 2021 | 59 | 1.210 |
Why?
| | Patient Compliance | 6 | 2017 | 55 | 1.200 |
Why?
| | Sweden | 15 | 2024 | 28 | 1.200 |
Why?
| | Retrospective Studies | 11 | 2024 | 1296 | 1.110 |
Why?
| | Biomedical Technology | 3 | 2023 | 5 | 1.090 |
Why?
| | Risk Factors | 12 | 2024 | 487 | 1.070 |
Why?
| | Medication Adherence | 4 | 2018 | 21 | 1.060 |
Why?
| | Surveys and Questionnaires | 10 | 2023 | 274 | 0.980 |
Why?
| | Meals | 7 | 2024 | 15 | 0.980 |
Why?
| | Magnetic Resonance Imaging | 4 | 2024 | 122 | 0.970 |
Why?
| | Spatio-Temporal Analysis | 1 | 2024 | 2 | 0.970 |
Why?
| | Insulin Glargine | 1 | 2024 | 1 | 0.970 |
Why?
| | Mobile Applications | 4 | 2020 | 16 | 0.950 |
Why?
| | Risk Assessment | 6 | 2024 | 137 | 0.950 |
Why?
| | Glucose | 9 | 2024 | 22 | 0.940 |
Why?
| | Thromboembolism | 1 | 2023 | 3 | 0.900 |
Why?
| | Young Adult | 16 | 2024 | 647 | 0.890 |
Why?
| | Neuralgia | 1 | 2023 | 1 | 0.890 |
Why?
| | Hyperalgesia | 1 | 2023 | 2 | 0.880 |
Why?
| | Time Factors | 3 | 2021 | 250 | 0.860 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 11 | 0.850 |
Why?
| | Social Support | 1 | 2022 | 25 | 0.820 |
Why?
| | Exercise | 7 | 2024 | 140 | 0.810 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 25 | 0.780 |
Why?
| | Capillaries | 1 | 2021 | 1 | 0.770 |
Why?
| | Blood Specimen Collection | 1 | 2021 | 5 | 0.770 |
Why?
| | Cost of Illness | 2 | 2020 | 19 | 0.750 |
Why?
| | Family Conflict | 3 | 2021 | 3 | 0.750 |
Why?
| | Insulin-Secreting Cells | 4 | 2023 | 4 | 0.750 |
Why?
| | Self Efficacy | 2 | 2017 | 14 | 0.720 |
Why?
| | Aging | 2 | 2019 | 39 | 0.700 |
Why?
| | Quality Improvement | 2 | 2019 | 60 | 0.680 |
Why?
| | Health Plan Implementation | 1 | 2019 | 9 | 0.680 |
Why?
| | Fear | 6 | 2023 | 17 | 0.670 |
Why?
| | Child Development | 1 | 2019 | 44 | 0.660 |
Why?
| | Treatment Outcome | 9 | 2024 | 622 | 0.660 |
Why?
| | Reproducibility of Results | 9 | 2024 | 199 | 0.660 |
Why?
| | Feeding Behavior | 3 | 2024 | 50 | 0.650 |
Why?
| | Diet, Diabetic | 2 | 2015 | 2 | 0.650 |
Why?
| | Prospective Studies | 13 | 2022 | 525 | 0.640 |
Why?
| | Quality of Life | 4 | 2024 | 140 | 0.640 |
Why?
| | Adolescent Behavior | 3 | 2016 | 43 | 0.620 |
Why?
| | Cross-Sectional Studies | 13 | 2022 | 336 | 0.610 |
Why?
| | Parenting | 4 | 2018 | 24 | 0.590 |
Why?
| | Follow-Up Studies | 13 | 2022 | 304 | 0.570 |
Why?
| | United States | 9 | 2021 | 669 | 0.550 |
Why?
| | Longitudinal Studies | 5 | 2024 | 119 | 0.540 |
Why?
| | Child Behavior | 3 | 2016 | 30 | 0.530 |
Why?
| | Biomarkers | 6 | 2021 | 136 | 0.530 |
Why?
| | Albuminuria | 1 | 2015 | 12 | 0.520 |
Why?
| | Algorithms | 1 | 2016 | 105 | 0.520 |
Why?
| | Food | 1 | 2015 | 17 | 0.500 |
Why?
| | Models, Biological | 3 | 2019 | 65 | 0.460 |
Why?
| | Health Education | 1 | 2014 | 26 | 0.460 |
Why?
| | Orchidaceae | 2 | 2024 | 2 | 0.440 |
Why?
| | Health Personnel | 3 | 2023 | 25 | 0.440 |
Why?
| | Infant | 11 | 2020 | 1446 | 0.420 |
Why?
| | Cohort Studies | 7 | 2024 | 289 | 0.420 |
Why?
| | Insulins | 2 | 2022 | 2 | 0.420 |
Why?
| | Family | 2 | 2022 | 27 | 0.410 |
Why?
| | Artificial Intelligence | 2 | 2024 | 14 | 0.410 |
Why?
| | Minority Groups | 4 | 2019 | 17 | 0.410 |
Why?
| | Crohn Disease | 2 | 2022 | 25 | 0.390 |
Why?
| | Sleep | 4 | 2021 | 37 | 0.390 |
Why?
| | Age of Onset | 4 | 2020 | 28 | 0.380 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2021 | 41 | 0.370 |
Why?
| | Australia | 6 | 2024 | 10 | 0.370 |
Why?
| | Mothers | 2 | 2023 | 33 | 0.360 |
Why?
| | Models, Organizational | 1 | 2020 | 7 | 0.360 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 12 | 0.360 |
Why?
| | Research Design | 1 | 2020 | 63 | 0.350 |
Why?
| | Phylogeny | 3 | 2024 | 24 | 0.350 |
Why?
| | Biomedical Research | 1 | 2020 | 27 | 0.350 |
Why?
| | Dietary Carbohydrates | 2 | 2020 | 4 | 0.340 |
Why?
| | C-Peptide | 4 | 2023 | 5 | 0.340 |
Why?
| | Behavior Therapy | 2 | 2022 | 35 | 0.340 |
Why?
| | Pilot Projects | 3 | 2022 | 120 | 0.330 |
Why?
| | Prevalence | 5 | 2022 | 146 | 0.320 |
Why?
| | Neoplasm Grading | 4 | 2021 | 19 | 0.320 |
Why?
| | Case-Control Studies | 4 | 2023 | 215 | 0.310 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2018 | 65 | 0.310 |
Why?
| | Incidence | 4 | 2021 | 133 | 0.300 |
Why?
| | Sudden Infant Death | 2 | 1998 | 3 | 0.300 |
Why?
| | Austria | 4 | 2020 | 4 | 0.300 |
Why?
| | Germany | 4 | 2020 | 6 | 0.300 |
Why?
| | Hope | 2 | 2018 | 3 | 0.290 |
Why?
| | Socioeconomic Factors | 5 | 2020 | 53 | 0.290 |
Why?
| | Ambulatory Care Facilities | 2 | 2019 | 36 | 0.290 |
Why?
| | Parent-Child Relations | 4 | 2022 | 37 | 0.290 |
Why?
| | Self-Injurious Behavior | 2 | 2023 | 3 | 0.260 |
Why?
| | Ustekinumab | 2 | 2022 | 2 | 0.260 |
Why?
| | Patient Education as Topic | 4 | 2018 | 53 | 0.250 |
Why?
| | Motivation | 2 | 2022 | 16 | 0.250 |
Why?
| | Developed Countries | 3 | 2020 | 4 | 0.250 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 99 | 0.250 |
Why?
| | Accelerometry | 2 | 2022 | 47 | 0.240 |
Why?
| | Aged, 80 and over | 3 | 2020 | 151 | 0.240 |
Why?
| | Starfish | 1 | 2024 | 1 | 0.240 |
Why?
| | Anthozoa | 1 | 2024 | 1 | 0.240 |
Why?
| | Insulin Lispro | 1 | 2024 | 1 | 0.240 |
Why?
| | Cues | 1 | 2024 | 5 | 0.240 |
Why?
| | Genes, Plant | 1 | 2024 | 1 | 0.240 |
Why?
| | Evolution, Molecular | 1 | 2024 | 6 | 0.240 |
Why?
| | Technology | 1 | 2024 | 3 | 0.240 |
Why?
| | Climate | 1 | 2024 | 4 | 0.230 |
Why?
| | Infant, Newborn | 6 | 2020 | 816 | 0.230 |
Why?
| | Sick Leave | 2 | 2022 | 2 | 0.230 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 34 | 0.230 |
Why?
| | Insulin, Regular, Human | 4 | 2024 | 4 | 0.230 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2023 | 2 | 0.230 |
Why?
| | Sex Factors | 4 | 2020 | 68 | 0.230 |
Why?
| | Myelodysplastic Syndromes | 1 | 2023 | 11 | 0.230 |
Why?
| | Stress, Psychological | 3 | 2020 | 32 | 0.230 |
Why?
| | Pediatrics | 2 | 2019 | 186 | 0.220 |
Why?
| | Suicide | 1 | 2023 | 5 | 0.220 |
Why?
| | Interleukin-10 | 1 | 2023 | 5 | 0.220 |
Why?
| | Genetic Therapy | 1 | 2023 | 7 | 0.220 |
Why?
| | DNA | 1 | 2023 | 41 | 0.220 |
Why?
| | Animals | 8 | 2024 | 729 | 0.220 |
Why?
| | Genomics | 1 | 2024 | 101 | 0.220 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 42 | 0.220 |
Why?
| | Prediabetic State | 1 | 2022 | 3 | 0.210 |
Why?
| | Prostate | 2 | 2021 | 7 | 0.210 |
Why?
| | Carrier Proteins | 3 | 2017 | 35 | 0.210 |
Why?
| | Cholera | 1 | 2022 | 1 | 0.210 |
Why?
| | Cholera Vaccines | 1 | 2022 | 1 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 55 | 0.210 |
Why?
| | Islets of Langerhans | 2 | 2013 | 3 | 0.210 |
Why?
| | Plant Viruses | 1 | 2022 | 1 | 0.200 |
Why?
| | RNA Viruses | 1 | 2022 | 3 | 0.200 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 65 | 0.200 |
Why?
| | Problem Behavior | 1 | 2022 | 7 | 0.200 |
Why?
| | Comorbidity | 1 | 2022 | 56 | 0.200 |
Why?
| | Income | 2 | 2020 | 17 | 0.200 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 13 | 0.200 |
Why?
| | Quality-Adjusted Life Years | 1 | 2021 | 2 | 0.200 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2021 | 2 | 0.190 |
Why?
| | ABO Blood-Group System | 1 | 2021 | 11 | 0.190 |
Why?
| | Disease Susceptibility | 1 | 2021 | 11 | 0.190 |
Why?
| | Veins | 1 | 2021 | 3 | 0.190 |
Why?
| | Inflammation | 2 | 2019 | 51 | 0.190 |
Why?
| | Conservation of Natural Resources | 1 | 2021 | 1 | 0.190 |
Why?
| | Rainforest | 1 | 2021 | 1 | 0.190 |
Why?
| | Postprandial Period | 3 | 2020 | 18 | 0.190 |
Why?
| | Child Health | 1 | 2021 | 7 | 0.190 |
Why?
| | Specimen Handling | 1 | 2021 | 17 | 0.190 |
Why?
| | Diabetes Complications | 1 | 2020 | 2 | 0.190 |
Why?
| | Midwestern United States | 5 | 2021 | 34 | 0.190 |
Why?
| | Pediatric Obesity | 1 | 2023 | 137 | 0.180 |
Why?
| | Hospitalization | 1 | 2022 | 210 | 0.180 |
Why?
| | Disease Management | 2 | 2019 | 34 | 0.180 |
Why?
| | Efficiency | 1 | 2020 | 1 | 0.180 |
Why?
| | Dihydroxycholecalciferols | 1 | 2020 | 1 | 0.180 |
Why?
| | Patient Care | 1 | 2020 | 6 | 0.180 |
Why?
| | Life Change Events | 1 | 2020 | 3 | 0.180 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 1 | 0.180 |
Why?
| | Vitamin D | 1 | 2020 | 22 | 0.180 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2020 | 22 | 0.180 |
Why?
| | Watchful Waiting | 1 | 2020 | 7 | 0.180 |
Why?
| | Health Care Costs | 1 | 2020 | 33 | 0.180 |
Why?
| | Risk | 3 | 2015 | 41 | 0.180 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 150 | 0.180 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 39 | 0.170 |
Why?
| | Professional Practice | 1 | 2019 | 4 | 0.170 |
Why?
| | Luxembourg | 1 | 2019 | 1 | 0.170 |
Why?
| | Datasets as Topic | 1 | 2019 | 7 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2019 | 19 | 0.170 |
Why?
| | Healthcare Disparities | 1 | 2019 | 22 | 0.170 |
Why?
| | Reference Values | 3 | 2015 | 39 | 0.170 |
Why?
| | Androgen-Binding Protein | 1 | 1999 | 1 | 0.170 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 23 | 0.170 |
Why?
| | Saliva | 1 | 1999 | 10 | 0.170 |
Why?
| | Program Evaluation | 1 | 2019 | 45 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2019 | 2 | 0.170 |
Why?
| | Testosterone | 1 | 1999 | 30 | 0.170 |
Why?
| | Feeding and Eating Disorders | 1 | 2019 | 8 | 0.170 |
Why?
| | Carbohydrates | 1 | 2018 | 2 | 0.160 |
Why?
| | Authoritarianism | 1 | 2018 | 1 | 0.160 |
Why?
| | Oxidative Stress | 2 | 2015 | 17 | 0.160 |
Why?
| | Nutrition Surveys | 1 | 2018 | 7 | 0.160 |
Why?
| | Dyslipidemias | 1 | 2018 | 15 | 0.160 |
Why?
| | Prognosis | 4 | 2020 | 211 | 0.160 |
Why?
| | Nutritional Status | 1 | 2018 | 17 | 0.160 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2018 | 3 | 0.160 |
Why?
| | Eating | 1 | 2018 | 31 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 23 | 0.150 |
Why?
| | Papillomavirus Infections | 1 | 2018 | 8 | 0.150 |
Why?
| | Delivery of Health Care | 2 | 2019 | 33 | 0.150 |
Why?
| | Diabetic Angiopathies | 1 | 2017 | 1 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 5 | 0.150 |
Why?
| | Aortic Diseases | 1 | 2017 | 4 | 0.150 |
Why?
| | Pandemics | 3 | 2023 | 82 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 22 | 0.150 |
Why?
| | ROC Curve | 3 | 2022 | 22 | 0.140 |
Why?
| | Stroke | 1 | 2017 | 22 | 0.140 |
Why?
| | Health Behavior | 1 | 2017 | 50 | 0.140 |
Why?
| | Blood Pressure | 1 | 2017 | 67 | 0.140 |
Why?
| | Sleep Deprivation | 1 | 2016 | 1 | 0.140 |
Why?
| | Hypertension | 1 | 2017 | 66 | 0.140 |
Why?
| | Optimism | 1 | 2015 | 2 | 0.130 |
Why?
| | Nutrition Policy | 1 | 2015 | 4 | 0.130 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2015 | 1 | 0.130 |
Why?
| | Child Nutrition Sciences | 1 | 2015 | 2 | 0.130 |
Why?
| | Metformin | 1 | 2015 | 5 | 0.130 |
Why?
| | Forkhead Transcription Factors | 1 | 2015 | 6 | 0.130 |
Why?
| | Heart Failure | 1 | 2015 | 14 | 0.130 |
Why?
| | Food Supply | 1 | 2015 | 9 | 0.130 |
Why?
| | Osteocalcin | 1 | 2015 | 1 | 0.130 |
Why?
| | Kansas | 1 | 2015 | 43 | 0.130 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 8 | 0.130 |
Why?
| | Insurance Coverage | 1 | 2015 | 21 | 0.130 |
Why?
| | Endothelial Cells | 1 | 2015 | 25 | 0.130 |
Why?
| | Rats | 4 | 2017 | 106 | 0.120 |
Why?
| | Sunlight | 1 | 2014 | 1 | 0.120 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2014 | 1 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2014 | 5 | 0.120 |
Why?
| | Calcifediol | 1 | 2014 | 3 | 0.120 |
Why?
| | Lymphocytes | 1 | 2014 | 15 | 0.120 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 190 | 0.120 |
Why?
| | Body Mass Index | 1 | 2015 | 157 | 0.120 |
Why?
| | Health Planning | 1 | 2013 | 2 | 0.110 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 1 | 0.110 |
Why?
| | Cyclin D1 | 1 | 2013 | 2 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2013 | 15 | 0.110 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 8 | 0.110 |
Why?
| | Forecasting | 1 | 2013 | 22 | 0.110 |
Why?
| | Transcriptional Activation | 1 | 2013 | 9 | 0.110 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 8 | 0.110 |
Why?
| | Marital Therapy | 1 | 1993 | 1 | 0.110 |
Why?
| | Marriage | 1 | 1993 | 2 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2023 | 44 | 0.110 |
Why?
| | DNA Methylation | 1 | 2014 | 115 | 0.110 |
Why?
| | Suicidal Ideation | 2 | 2023 | 6 | 0.110 |
Why?
| | Communication | 1 | 1993 | 46 | 0.110 |
Why?
| | Signal Transduction | 1 | 2013 | 132 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 101 | 0.100 |
Why?
| | RNA, Viral | 2 | 2022 | 13 | 0.100 |
Why?
| | Cell Cycle Proteins | 3 | 2017 | 18 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 3 | 2017 | 50 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2013 | 58 | 0.100 |
Why?
| | Remission Induction | 2 | 2022 | 24 | 0.100 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2011 | 1 | 0.100 |
Why?
| | Bone Marrow | 1 | 2011 | 6 | 0.100 |
Why?
| | Graft Survival | 1 | 2011 | 31 | 0.100 |
Why?
| | Neoplasms | 1 | 2013 | 128 | 0.090 |
Why?
| | Internationality | 2 | 2021 | 6 | 0.090 |
Why?
| | Cholesterol, LDL | 2 | 2023 | 7 | 0.090 |
Why?
| | Nuclear Proteins | 2 | 2024 | 52 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2020 | 24 | 0.090 |
Why?
| | Anxiety | 2 | 2020 | 51 | 0.090 |
Why?
| | England | 2 | 2020 | 2 | 0.080 |
Why?
| | Norway | 2 | 2020 | 2 | 0.080 |
Why?
| | Wales | 2 | 2020 | 2 | 0.080 |
Why?
| | New Zealand | 2 | 1998 | 4 | 0.080 |
Why?
| | Mice | 3 | 2015 | 348 | 0.080 |
Why?
| | Hepatectomy | 1 | 2007 | 4 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 22 | 0.070 |
Why?
| | Liver Diseases | 1 | 2007 | 18 | 0.070 |
Why?
| | Electronic Health Records | 2 | 2018 | 64 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 9 | 0.070 |
Why?
| | Liver | 1 | 2007 | 126 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 46 | 0.070 |
Why?
| | Transcription Factors | 2 | 2015 | 52 | 0.060 |
Why?
| | Cardiovascular Diseases | 2 | 2015 | 48 | 0.060 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 187 | 0.060 |
Why?
| | Rhodophyta | 1 | 2024 | 1 | 0.060 |
Why?
| | Ecosystem | 1 | 2024 | 1 | 0.060 |
Why?
| | Coral Reefs | 1 | 2024 | 1 | 0.060 |
Why?
| | Herbivory | 1 | 2024 | 1 | 0.060 |
Why?
| | Sports | 1 | 2004 | 4 | 0.060 |
Why?
| | Athletic Injuries | 1 | 2004 | 3 | 0.060 |
Why?
| | Workload | 1 | 2004 | 9 | 0.060 |
Why?
| | Fossils | 1 | 2024 | 1 | 0.060 |
Why?
| | Phylogeography | 1 | 2024 | 1 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2024 | 38 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 10 | 0.060 |
Why?
| | Uncertainty | 1 | 2023 | 10 | 0.060 |
Why?
| | Snacks | 1 | 2023 | 6 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2013 | 115 | 0.060 |
Why?
| | Isoantibodies | 1 | 2023 | 8 | 0.060 |
Why?
| | Erythrocytes | 1 | 2023 | 11 | 0.060 |
Why?
| | Age Factors | 2 | 2015 | 210 | 0.060 |
Why?
| | Hemoglobins | 1 | 2023 | 27 | 0.060 |
Why?
| | Verapamil | 1 | 2023 | 3 | 0.060 |
Why?
| | Overweight | 1 | 2023 | 49 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 71 | 0.050 |
Why?
| | Space Perception | 1 | 1982 | 2 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 12 | 0.050 |
Why?
| | Reference Standards | 1 | 2022 | 15 | 0.050 |
Why?
| | Autoantibodies | 1 | 2022 | 11 | 0.050 |
Why?
| | Risk-Taking | 1 | 2022 | 11 | 0.050 |
Why?
| | Travel | 1 | 2022 | 6 | 0.050 |
Why?
| | Interleukin-23 | 1 | 2022 | 2 | 0.050 |
Why?
| | Administration, Oral | 1 | 2022 | 58 | 0.050 |
Why?
| | Plant Diseases | 1 | 2022 | 1 | 0.050 |
Why?
| | Genome, Viral | 1 | 2022 | 4 | 0.050 |
Why?
| | Viral Proteins | 1 | 2022 | 8 | 0.050 |
Why?
| | Executive Function | 1 | 2022 | 10 | 0.050 |
Why?
| | Disease Progression | 1 | 2022 | 111 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 71 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2015 | 84 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2021 | 1 | 0.050 |
Why?
| | Random Allocation | 1 | 2021 | 7 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 7 | 0.050 |
Why?
| | Chronic Disease | 1 | 2021 | 105 | 0.050 |
Why?
| | Blood Donors | 1 | 2021 | 1 | 0.050 |
Why?
| | Kidney Calculi | 1 | 2021 | 1 | 0.050 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2021 | 1 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 8 | 0.050 |
Why?
| | Bedding and Linens | 2 | 1998 | 2 | 0.050 |
Why?
| | Blood Transfusion | 1 | 2021 | 13 | 0.050 |
Why?
| | Forests | 1 | 2021 | 1 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2021 | 30 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 99 | 0.050 |
Why?
| | Seasons | 1 | 2021 | 35 | 0.050 |
Why?
| | Photography | 1 | 2020 | 4 | 0.050 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 4 | 0.050 |
Why?
| | Observer Variation | 1 | 2020 | 16 | 0.050 |
Why?
| | Avoidance Learning | 1 | 2020 | 6 | 0.050 |
Why?
| | Benchmarking | 1 | 2020 | 11 | 0.040 |
Why?
| | Pensions | 1 | 2020 | 1 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 50 | 0.040 |
Why?
| | Prostatectomy | 1 | 2020 | 4 | 0.040 |
Why?
| | Radiotherapy | 1 | 2020 | 5 | 0.040 |
Why?
| | Pregnancy | 1 | 2021 | 216 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2020 | 45 | 0.040 |
Why?
| | Emigrants and Immigrants | 1 | 2019 | 2 | 0.040 |
Why?
| | Infusion Pumps, Implantable | 1 | 2019 | 2 | 0.040 |
Why?
| | Longevity | 1 | 2019 | 3 | 0.040 |
Why?
| | Databases, Factual | 1 | 2020 | 108 | 0.040 |
Why?
| | Health Educators | 1 | 2019 | 1 | 0.040 |
Why?
| | Linear Models | 1 | 2019 | 56 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 58 | 0.040 |
Why?
| | Autoradiography | 1 | 1999 | 1 | 0.040 |
Why?
| | Electrophoresis | 1 | 1999 | 1 | 0.040 |
Why?
| | Dihydrotestosterone | 1 | 1999 | 2 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 4 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 3 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 6 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 1999 | 32 | 0.040 |
Why?
| | Homozygote | 1 | 1999 | 20 | 0.040 |
Why?
| | E-Selectin | 1 | 2019 | 1 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2019 | 6 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2019 | 16 | 0.040 |
Why?
| | Medical Overuse | 1 | 2018 | 1 | 0.040 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2018 | 2 | 0.040 |
Why?
| | Computers, Handheld | 1 | 2018 | 8 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2018 | 11 | 0.040 |
Why?
| | Denmark | 1 | 2018 | 1 | 0.040 |
Why?
| | Gene Expression | 2 | 2015 | 67 | 0.040 |
Why?
| | Data Collection | 1 | 2018 | 29 | 0.040 |
Why?
| | Scandinavian and Nordic Countries | 1 | 2018 | 1 | 0.040 |
Why?
| | Psychometrics | 1 | 2018 | 30 | 0.040 |
Why?
| | Health Policy | 1 | 2018 | 14 | 0.040 |
Why?
| | Databases as Topic | 1 | 2017 | 2 | 0.040 |
Why?
| | Glycemic Index | 1 | 2017 | 2 | 0.040 |
Why?
| | Genetic Variation | 1 | 1999 | 174 | 0.040 |
Why?
| | Directive Counseling | 1 | 2016 | 6 | 0.040 |
Why?
| | Breast Feeding | 1 | 1996 | 25 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 7 | 0.030 |
Why?
| | Schools, Veterinary | 1 | 1976 | 1 | 0.030 |
Why?
| | Gonads | 1 | 1995 | 2 | 0.030 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 1995 | 3 | 0.030 |
Why?
| | Adrenal Glands | 1 | 1995 | 6 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 13 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2015 | 4 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 1995 | 39 | 0.030 |
Why?
| | Peer Influence | 1 | 2015 | 1 | 0.030 |
Why?
| | Diet Records | 1 | 2015 | 5 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2015 | 1 | 0.030 |
Why?
| | Thioredoxins | 1 | 2015 | 1 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2015 | 7 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 9 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 14 | 0.030 |
Why?
| | Aorta | 1 | 2015 | 8 | 0.030 |
Why?
| | Food Preferences | 1 | 2015 | 11 | 0.030 |
Why?
| | Caspase 7 | 1 | 2015 | 1 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 3 | 0.030 |
Why?
| | Caspase 3 | 1 | 2015 | 3 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 17 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 20 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 26 | 0.030 |
Why?
| | Mitochondria | 1 | 2015 | 11 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 22 | 0.030 |
Why?
| | Apoptosis | 1 | 2015 | 52 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 38 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 99 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 94 | 0.030 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2014 | 1 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 1994 | 1 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 1994 | 18 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 6 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2013 | 13 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 3 | 0.030 |
Why?
| | Survivors | 1 | 2013 | 18 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 8 | 0.030 |
Why?
| | Phosphorylation | 1 | 2013 | 22 | 0.030 |
Why?
| | Survival Rate | 1 | 2013 | 83 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2013 | 8 | 0.030 |
Why?
| | Time | 1 | 2013 | 6 | 0.030 |
Why?
| | Glucagon | 1 | 2013 | 3 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2013 | 12 | 0.030 |
Why?
| | Cell Line | 1 | 2013 | 81 | 0.030 |
Why?
| | Pancreas | 1 | 2013 | 8 | 0.030 |
Why?
| | Problem Solving | 1 | 1993 | 2 | 0.030 |
Why?
| | Protein Binding | 1 | 2013 | 31 | 0.030 |
Why?
| | Recurrence | 1 | 2013 | 110 | 0.030 |
Why?
| | Proteomics | 1 | 2013 | 24 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 35 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2013 | 39 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 85 | 0.030 |
Why?
| | Folic Acid | 1 | 2011 | 17 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2011 | 2 | 0.020 |
Why?
| | Methotrexate | 1 | 2011 | 30 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2011 | 4 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 2 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 4 | 0.020 |
Why?
| | Arthritis, Juvenile | 1 | 2011 | 31 | 0.020 |
Why?
| | Osteoblasts | 1 | 2011 | 21 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 126 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 410 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2011 | 176 | 0.020 |
Why?
| | Integrin alpha6 | 1 | 2007 | 1 | 0.020 |
Why?
| | Oncostatin M | 1 | 2007 | 1 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2007 | 2 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2007 | 2 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2007 | 5 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 7 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 8 | 0.020 |
Why?
| | Glycoproteins | 1 | 2007 | 9 | 0.020 |
Why?
| | Hepatocytes | 1 | 2007 | 8 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2007 | 32 | 0.020 |
Why?
| | Peptides | 1 | 2007 | 11 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2007 | 59 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2007 | 47 | 0.020 |
Why?
| | Phenotype | 1 | 2007 | 257 | 0.020 |
Why?
| | New South Wales | 1 | 2004 | 1 | 0.020 |
Why?
| | Causality | 1 | 2004 | 10 | 0.010 |
Why?
| | Thinking | 1 | 1982 | 2 | 0.010 |
Why?
| | Psychology, Adolescent | 1 | 1982 | 6 | 0.010 |
Why?
| | Rehabilitation Centers | 1 | 1977 | 3 | 0.010 |
Why?
| | Alcoholism | 1 | 1977 | 4 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1977 | 26 | 0.010 |
Why?
| | Agriculture | 1 | 1976 | 1 | 0.010 |
Why?
| | Education, Veterinary | 1 | 1976 | 1 | 0.010 |
Why?
| | Financing, Government | 1 | 1976 | 1 | 0.010 |
Why?
| | School Admission Criteria | 1 | 1976 | 1 | 0.010 |
Why?
| | History, 19th Century | 1 | 1976 | 1 | 0.010 |
Why?
| | Education | 1 | 1976 | 3 | 0.010 |
Why?
| | History, 20th Century | 1 | 1976 | 6 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1995 | 1 | 0.010 |
Why?
| | Steroidogenic Factor 1 | 1 | 1995 | 1 | 0.010 |
Why?
| | Zinc Fingers | 1 | 1995 | 2 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1995 | 6 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1995 | 11 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1995 | 4 | 0.010 |
Why?
| | Repressor Proteins | 1 | 1995 | 12 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 30 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1995 | 20 | 0.010 |
Why?
| | Mice, Knockout | 1 | 1995 | 59 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 81 | 0.010 |
Why?
| | Placenta | 1 | 1995 | 21 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1995 | 37 | 0.010 |
Why?
| | Clothing | 1 | 1994 | 1 | 0.010 |
Why?
| | Skin Temperature | 1 | 1994 | 1 | 0.010 |
Why?
| | Temperature | 1 | 1994 | 12 | 0.010 |
Why?
| | Acute Disease | 1 | 1994 | 79 | 0.010 |
Why?
| | Maryland | 1 | 1977 | 3 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1977 | 8 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|